Pacira BioSciences, Inc.
PCRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 16, 2026 close
- Market cap
- $1.46B
- P/E (TTM)
- 100.02
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $18.80$36.48
- Volume (live)
- -
- Avg. volume (3M)
- 1.86M
Pacira BioSciences (PCRX) Stock Price & Financial Analysis
Pacira BioSciences Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $36.32 - $36.39 |
|---|---|
| 52-Week High | $36.48 |
| 52-Week Low | $18.80 |
| Open | $36.38 |
| Volume (last close) | 960.90K |
| Average Volume (3M) | 1.86M |
| Revenue (TTM) | 746.16M |
|---|---|
| Net Income (TTM) | 14.64M |
| Free Cash Flow (TTM) | 179.51M |
| EPS (TTM) | $0.35 |
| Profit Margin | 1.96% |
| Operating Margin | 2.47% |
| Return on Equity (ROE) | 2.18% |
| Debt to Equity | 0.56 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 1.46B |
|---|---|
| Shares Outstanding | 40.30M |
| P/E Ratio (TTM) | 100.02 |
| Price to Sales (P/S) | 1.96 |
| Price to Book (P/B) | 2.18 |
| EV/EBITDA | 14.22 |
| 50-Day MA | $26.13 |
|---|---|
| 200-Day MA | $24.14 |
| 1-Year Change | +58.85% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Pacira BioSciences at a Glance
As of the Oct 16, 2026 close, Pacira BioSciences (PCRX) has a market capitalization of $1.46B. The stock trades at 100.0× trailing earnings and 2.0× sales. Over the trailing twelve months it earned $14.64M on revenue of $746.16M (a 2.0% profit margin) and generated $179.51M of free cash flow. Revenue grew 5.7% year over year.
As of its latest reported balance sheet, it holds $205.88M in cash and securities against $373.42M of debt, a net debt position of $167.55M.
Pacira BioSciences does not currently pay a dividend.
The share price is up 58.9% over the past year. At $36.34 (the Oct 16, 2026 close) it sits near the top of its 52-week range of $18.80 to $36.48, above its 200-day moving average of $24.14.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $32.86, 9.6% below the Oct 16, 2026 close.
Frequently Asked Questions About Pacira BioSciences
What is the current stock price for PCRX?
As of the Oct 16, 2026 close, PCRX stock trades at $36.34. The 52-week range is $18.80–$36.48, with a day range of $36.32–$36.39.
What is the P/E ratio for PCRX?
As of the Oct 16, 2026 close, Pacira BioSciences's trailing twelve-month (TTM) P/E ratio is 100.0, meaning investors pay $100.0 for every $1 of annual earnings. Pacira BioSciences operates in the Healthcare sector.
Does PCRX pay dividends?
Pacira BioSciences does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for PCRX?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for PCRX is Hold. The average 12-month price target is $32.86, a 9.6% downside from the Oct 16, 2026 close of $36.34.
What is the market cap of PCRX?
As of the Oct 16, 2026 close, Pacira BioSciences's market capitalization is $1.46B, classifying it as a small-cap company. Pacira BioSciences operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.